SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology 1999; 38: 120812.
  • 2
    Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation, 1982–1985. Arthritis Rheum 1987; 30: 2949.
  • 3
    Franzen P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988. J Rheumatol 1992; 19: 2736.
  • 4
    Noltorp S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 3515.
  • 5
    Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway, 1987–1994. J Rheumatol 1997; 24: 173943.
  • 6
    Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland: an epidemiologic and histopathologic analysis. Arthritis Rheum 1994; 37: 100712.
  • 7
    Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88: 1627.
  • 8
    Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 1924.
  • 9
    Salvarani C, Macchioni PL, Zizzi F, Mantovani W, Rossi F, Castri C, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 3516.
  • 10
    Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern area of Spain: trend over an 18 year period. Ann Rheum Dis 2001; 60: 36771.
  • 11
    Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br J Rheumatol 1994; 33: 93841.
  • 12
    Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995; 122: 5027.
  • 13
    Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am 1981; 245: 5463.
  • 14
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 11228.
  • 15
    Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 67280.
  • 16
    Cherry J. Parvoviruses. In: Feigin R, Cherry J, editors. Textbook of pediatric infectious diseases. Vol 3. Philadelphia: WB Saunders; 1992. p. 162633.
  • 17
    Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 1129.
  • 18
    Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999; 42: 12558.
  • 19
    Regan MJ, Wood BJ, Hsieh YH, Theodore ML, Quinn TC, Hellmann DB, et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002; 46: 105660.
  • 20
    Salvarani C, Farnetti E, Casali B, Nicoli D, Wenlan L, Bajocchi GL, et al. Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study. Arthritis Rheum 2002; 46: 3099101.
  • 21
    Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002; 41: 4459.
  • 22
    Andersson R, Malmvall BE, Bengtsson BA. Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica: a follow-up study of 90 patients treated with corticosteroids. Acta Med Scand 1986; 220: 3614.
  • 23
    Gonzalez-Gay MA, Blanco R, Abraira V, Garcia-Porrua C, Ibanez D, Garcia-Pais MJ, et al. Giant cell arterits in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 1997; 24: 21716.
  • 24
    Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology 2001; 40: 123842.
  • 25
    Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996; 100: 1936.
  • 26
    Bisgard C, Sloth H, Keiding N, Juel K. Excess mortality in giant cell arteritis. J Intern Med 1991; 230: 11923.
  • 27
    Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 12836.
  • 28
    Uddhammar A, Eriksson AL, Nystrom L, Stenling R, Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002; 29: 73742.